Polypeptide Inhibitors Targeting Nuclear Speckle Association
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective tools to toggle the functional outcomes of transcription factors and target nuclear speckles, which are critical in regulating gene expression and are implicated in diseases such as cancer, particularly in shifting pathways that promote cancer cell growth and metastasis.
Innovation Solution
Development of polypeptides that inhibit transcription factor/DNA-speckle association, comprising a cell-penetrating peptide, a linker region, and a DNA-speckle targeting motif, which can be used to manipulate nuclear speckle content and treat speckle-related cancers by disrupting the association of transcription factors like p53 and HIF2A with DNA speckles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If transcription factors are activated to drive gene expression, then gene expression regulation is improved, but cancer cell growth and metastasis are promoted
Solution Approach 1:
The patent uses a polypeptide inhibitor as an intermediary molecule that binds to transcription factors (p53, HIF2A) and blocks their interaction with nuclear speckles. This mediator prevents the transcription factors from driving cancer-promoting gene expression programs while allowing other cellular functions to continue, thereby resolving the contradiction between maintaining transcription factor activity and preventing cancer progression.
Solution Approach 2:
The invention extracts and targets the specific DNA-speckle association function of transcription factors using a polypeptide inhibitor. By selectively inhibiting the transcription factor/DNA-speckle interaction while leaving other transcription factor functions intact, the patent removes the harmful cancer-promoting pathway without completely eliminating transcription factor activity, thus resolving the contradiction.
2Reliability
If polypeptide inhibitors are developed to block transcription factor/DNA-speckle association, then cancer therapy efficacy is improved, but device complexity increases
Solution Approach 1:
The polypeptide inhibitor is segmented into distinct functional domains: a cell-penetrating peptide domain for cellular uptake, a linker region for flexibility and spacing, and a DNA-speckle targeting motif for specific binding. This segmentation allows each domain to perform its specialized function independently, achieving high therapeutic efficacy while maintaining a manageable structural complexity through modular design.
Solution Approach 2:
The patent creates a composite polypeptide structure that combines different functional elements (cell-penetrating peptide, linker, DNA-speckle targeting motif) into a single molecule. This composite approach integrates multiple functions into one therapeutic agent, improving cancer therapy efficacy by ensuring cellular uptake, proper positioning, and specific target binding simultaneously, while the systematic combination of known motifs keeps the overall complexity controlled.
Data Source
AI summary
The present invention provides polypeptides, compositions, and methods useful for the inhibition of transcription factor/DNA-speckle association and for manipulation of nuclear speckle content. Also included are methods of treating speckle related cancers in subjects in need thereof.